Serum levels of arachidonic acid metabolites change during prostate cancer progression. - Wikidata - wikimedia - TriplyDB

Serum levels of arachidonic acid metabolites change during prostate cancer progression.

Serum levels of arachidonic acid metabolites change during prostate cancer progression.

http://www.wikidata.org/entity/Q34398467

about

Emerging Role of Nutri-Epigenetics in Inflammation and Cancer Measurement of Serum and Hepatic Eicosanoids by Liquid Chromatography Tandem-Mass Spectrometry (LC-MS/MS) in a Mouse Model of Hepatocellular Carcinoma (HCC) with Delivery of c-Met and Activated β-Catenin by Hepatocyte Hydrodynamic Injection.

P2860

Q41689921-7927A9CE-D8C0-4F97-AE00-477540568AB8 Q55003371-18F18499-9306-41F0-88B8-4F6B0885A998

P2860

Serum levels of arachidonic acid metabolites change during prostate cancer progression.

http://www.wikidata.org/entity/Q34398467

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Serum levels of arachidonic acid metabolites change during prostate cancer progression.

@ast

Serum levels of arachidonic acid metabolites change during prostate cancer progression.

@en

Serum levels of arachidonic acid metabolites change during prostate cancer progression.

@nl

type

label

Serum levels of arachidonic acid metabolites change during prostate cancer progression.

@ast

Serum levels of arachidonic acid metabolites change during prostate cancer progression.

@en

Serum levels of arachidonic acid metabolites change during prostate cancer progression.

@nl

prefLabel

Serum levels of arachidonic acid metabolites change during prostate cancer progression.

@ast

Serum levels of arachidonic acid metabolites change during prostate cancer progression.

@en

Serum levels of arachidonic acid metabolites change during prostate cancer progression.

@nl

P1433

Q34398467-337F5C88-432A-4595-83A6-27F4A35C7AA6

P1476

Q34398467-33AC399C-F5C5-4D99-B0ED-48AB611AF7F7

P2093

Q34398467-0CABC971-6DD5-4A98-8D96-FCA223DD2340

Q34398467-0D3DE260-3D05-47C7-855C-F2B6088A5630

Q34398467-578EC29D-51FA-44F1-8B83-86655C90767D

Q34398467-6B94D762-9E97-4729-AF1E-445C23D9A0FA

Q34398467-8CB232A8-6C99-4E74-AA96-67A80E709C25

Q34398467-9C1380AF-7818-41B8-8075-6E86555A4436

Q34398467-DA09A453-3FF0-48E9-9D5D-F7FFAB9D5DC7

Q34398467-FCA83D13-0957-4F6A-89CD-FE8E6A18EAAF

P2860

Q34398467-0AC88E89-E977-4ADE-B7F8-4D1EE36B9028

Q34398467-0D5393E6-BA80-4445-B10F-76E0453D9058

Q34398467-0F39D5E0-2253-46CD-B0E8-659FDB1BB001

Q34398467-1DDF1C1D-9FCC-435C-B365-D8BB17A99907

Q34398467-43348ACF-8718-421E-B002-411D4E251D05

Q34398467-44AE42A0-EBEE-476F-9F5F-6A31A8DE21B4

Q34398467-6084CDFC-634E-47BC-B9EE-1BF6A95FBBFE

Q34398467-62BCA144-037F-46E1-BEE4-F055D2BE7D02

Q34398467-6801BB28-FD80-4CBD-B4B2-A10E5380B35A

Q34398467-7253961A-98B7-4B92-B64A-CA7B6BA6D6C7

P304

Q34398467-3C213EA0-D985-4E64-913A-122A13CE64DB

P31

Q34398467-D0F9AD92-5E39-4C63-A217-03FE5CBFD891

P356

Q34398467-DFCE54D9-C43D-44F4-A3BB-15942DC404A8

P433

Q34398467-953B0FE6-6C56-4249-8B3F-E50E4149BF12

P478

Q34398467-55F5C53B-80D2-4695-95D1-FECBC9850334

P50

Q34398467-128C67B3-8233-47E8-9C1F-68CAE03646A8

P577

Q34398467-B1290948-5BA5-4A77-96C7-F48EA953DF41

P5875

Q34398467-61C080C2-848A-4E40-A663-AE03C991CB09

P698

Q34398467-D580451A-C8FA-48A5-A41D-C138B8A07F38

P356

P1433

P1476

Serum levels of arachidonic acid metabolites change during prostate cancer progression.

@en

P2093

Chris H Bangma

http://www.w3.org/2001/XMLSchema#string

Ellen A M Schenk-Braat

http://www.w3.org/2001/XMLSchema#string

Guido Jenster

http://www.w3.org/2001/XMLSchema#string

Jan J N Ijzermans

http://www.w3.org/2001/XMLSchema#string

Lennard J M Dekker

http://www.w3.org/2001/XMLSchema#string

Mark F Wildhagen

http://www.w3.org/2001/XMLSchema#string

Peter C Burgers

http://www.w3.org/2001/XMLSchema#string

Theo M Luider

http://www.w3.org/2001/XMLSchema#string

P2860

HMDB: a knowledgebase for the human metabolome

Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention

Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease

Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer

Lipoxygenase-5 is overexpressed in prostate adenocarcinoma.

15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma

Epoxygenase pathways of arachidonic acid metabolism.

Role of eicosanoids in prostate cancer progression.

Cytosolic phospholipase A2-alpha: a potential therapeutic target for prostate cancer

Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer.

P304

618-627

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PROS.22779

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

Giovanny Rodriguez Blanco

P577

2014-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259770992

http://www.w3.org/2001/XMLSchema#string

P698

24435810

http://www.w3.org/2001/XMLSchema#string